GW Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
June 06 2018 - 1:19PM
GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the
Group), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, announced that GW
management will present at the Goldman Sachs 39th Annual Global
Healthcare Conference on Wednesday, June 13, 2018 at 10:00 a.m. PT
at the Terranea Resort, in Rancho Palos Verde, CA.
A live audio webcast of the presentation will be
available through GW’s corporate website in the investor relations
section from the investor’s calendar of events page at
www.gwpharm.com. A replay will be available soon
after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW, along with its U.S.
subsidiary Greenwich Biosciences, is advancing an orphan drug
program in the field of childhood-onset epilepsy with a focus on
Epidiolex (cannabidiol), for which GW has submitted regulatory
applications in the U.S. and Europe for the adjunctive treatment of
Lennox-Gastaut syndrome and Dravet syndrome. The Company continues
to evaluate Epidiolex in additional rare epilepsy conditions and
currently has an ongoing clinical trial in Tuberous Sclerosis
Complex. GW commercialized the world’s first plant-derived
cannabinoid prescription drug, Sativex® (nabiximols), which is
approved for the treatment of spasticity due to multiple sclerosis
in numerous countries outside the United States and for which the
company is now planning a US Phase 3 trial. The Company has a deep
pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for epilepsy,
glioblastoma, and schizophrenia. For further information, please
visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations |
917 280 2424 / 401 500 6570 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024